Jeanny B. Aragon-Ching, MD of the Inova Schar Cancer Institute has co-authored a groundbreaking bladder cancer research paper just published in the New England Journal of Medicine.
The large phase III clinical study showed that the addition of immunotherapy with Avelumab (Bavencio) increased the duration of overall survival by almost 50% in patients when given after chemotherapy in patients with locally advanced bladder cancer.
This practice-changing study showed how the addition of immunotherapy can have a dramatic impact on the lives of patients with certain cancers.
Study at a glanceInova’s incidental lung nodule program has shown a 76% reduction in time…
Catherine Wymer, PharmD, is a senior clinical pharmacist at Inova 360° Concierge Medicine. As a…
Multidisciplinary pulmonary expertise supports diagnostic evaluation, treatment planning and longitudinal care Advanced lung disease and…
Heart failure is a major focus for Inova Schar Heart and Vascular’s care transformation efforts.…
TETON pivotal studies meet primary end point In two landmark phase 3 trials, nebulized Tyvaso®…
Leesburg, VA — Inova Blood Donor Services (IBDS) invites the Loudoun County community to roll…